Besponsa (inotuzumab ozogamicin) [product monograph]. HC.

Regulatory approval published by the Health Canada.

Citation

Pfizer Canada ULC. Besponsa (inotuzumab ozogamicin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077730.PDF. Revised November 2024. Accessed June 2025.

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
BESPONSA (inotuzumab ozogamicin for injection) is indicated for monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	CD22 +	Acute Lymphoid Leukemia	Inotuzumab ozogamicin